## Targeting cannabinoid 1 and delta opioid receptor heteromers alleviates chemotherapy-induced neuropathic pain

Salvador Sierra<sup>1,\*</sup>, Achla Gupta<sup>1</sup>, Ivone Gomes<sup>1</sup>, Mary Fowkes<sup>2</sup>, Akila Ram<sup>3</sup>, Erin N. Bobeck<sup>3</sup>, Lakshmi A. Devi<sup>1\*</sup>

<sup>1</sup>Department of Pharmacological Sciences and <sup>2</sup>Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; <sup>3</sup>Department of Biology, Utah State University, UT, USA

\*Corresponding Author:

Lakshmi A. Devi Department of Pharmacological Sciences Icahn School of Medicine at Mount Sinai, 19-90 Annenberg Building, One Gustave L. Levy Place, New York, NY10029,

E-mail: Lakshmi.devi@mssm.edu

**Current Address** Department of Physiology & Biophysics Molecular Medicine Research Building Virginia Commonwealth University 1220 East Broad Street Richmond, VA, 23298

Email: Salvador.Sierra@vcuhealth.org


## **Table of Contents**

Figure S1. Validation of antibodies

Figure S2. Cellular location of CB<sub>1</sub>R-DOR heteromers in the dorsal region of the lumbar spinal cord of paclitaxel-treated mice using PLA


Figure S3. CB<sub>1</sub>R-DOR heteromers are increased in the basolateral amygdala of paclitaxeltreated mice

**Table S1.** Summary information of control and patients with chemotherapy-induced peripheral neuropathy (CIPN)




Suppl. Fig.1

**Supl Fig 1. Validation of antibodies.**  $CB_1R$  and DOR staining is present in the cerebellar cortex or pontine gray of wild-type but not in  $CB_1R$  or DOR knock-out mice respectively. Tissue sections were stained using a goat rabbit anti- $CB_1R$  or anti-DOR receptor antibody followed by HRP-conjugated anti-species IgG secondary antibodies, and reaction with diaminobenzidine.



Suppl. Fig. 2

Supl Fig 2 Detection of CB<sub>1</sub>R-DOR heteromers in the dorsal region of the lumbar spinal cord of paclitaxel-treated mice using PLA. CB<sub>1</sub>R-DOR heteromers are located in neurons (somatodendritic and presynaptic location) and astrocytes, but not in microglia.



Suppl. Fig. 3

Supl Fig 3. CB<sub>1</sub>R-DOR heteromers are increased in the basolateral amygdala of paclitaxel-treated mice. CB<sub>1</sub>R-DOR heteromers (red dots in color panels, black dots in inverted color panels) are detected in the basolateral amygdala of control and paclitaxel-induced chemotherapy mice.

**Table S1.** Summary information of control and patients with chemotherapy-induced peripheral neuropathy (CIPN)

Control group			
sex	age (years)	cause of death	PLA (CB1R-DOR) dots
female	68	cardiac arrest 364	
female	30	cardiorespiratory failure	127
female	72	cardiac arrest	110
male	42	surgery complication	313
male	57	cardiac arrest	122
male	34	septic shock	147
male	38	cardiac arrest	257
male	50	multiorgan failure	164
male	64	procedure complication	218
male	56	cardiac arrest	358

CIPN group	1			
sex	age (years)	disease	drugs	PLA (CB1R-DOR) dots
female	49	pharynx carcinoma	paclitaxel, carboplatin	284
female	51	breast cancer	paclitaxel, carboplatin	721
female	51	multiple myeloma	cisplatin	370
male	48	larynx cancer	paclitaxel, oxaliplatin	362
male	75	larynx cancer	paclitaxel	426
male	70	lung cancer	paclitaxel	588
male	65	B-cell lymphoma	oxaliplatin	420
male	51	breast cancer	paclitaxel	728
male	73	tongue cancer	cisplatin	631